ArticleScientific reports2015
Nonerythropoietic Erythropoietin-Derived Peptide Suppresses Adipogenesis, Inflammation, Obesity and Insulin Resistance.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high-fat diet-induced obese mice.FEBS open bio · 2026Article
- Personalized Therapeutic Advances in Erythropoietin Signaling: From Anemia Management to Extensive Clinical Applications.Pharmaceutics · 2025Review
- Erythropoietin Attenuates Insulin Resistance and Renal Inflammation in High-Sucrose-Treated Rats.International journal of molecular sciences · 2025Article
- Non-hematopoietic roles of erythropoietin in inflammation and metabolic disorders.Frontiers in pharmacology · 2025Review
- The secreted peptide BATSP1 promotes thermogenesis in adipocytes.Cellular and molecular life sciences : CMLS · 2023Article
- Iron, glucose and fat metabolism and obesity: an intertwined relationship.International journal of obesity (2005) · 2023Review
- Research and prospect of peptides for use in obesity treatment (Review).Experimental and therapeutic medicine · 2020Review
- Erythropoietin prevents LPS-induced preterm birth and increases offspring survival.American journal of reproductive immunology (New York, N.Y. : 1989) · 2020Article
- Iron Metabolism in Obesity and Metabolic Syndrome.International journal of molecular sciences · 2020Review
- Erythropoiesis, EPO, macrophages, and bone.Bone · 2019Review
- The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research.Frontiers in physiology · 2019Review
- VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity.Scientific reports · 2018Article
- Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus.Journal of cellular and molecular medicine · 2018Article
- Erythropoietin protects against rhabdomyolysis-induced acute kidney injury by modulating macrophage polarization.Cell death & disease · 2017Article
- Article
- Salidroside improves glucose homeostasis in obese mice by repressing inflammation in white adipose tissues and improving leptin sensitivity in hypothalamus.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin (EPO) has been identified as being crucial for obesity modulation; however, its erythropoietic activity may limit its clinical application. EPO-derived Helix B-surface peptide (pHBSP) is nonerythrogenic but has been reported to retain other functions of EPO. The current study aimed to evaluate the effects and potential mechanisms of pHBSP in obesity modulation. We found that pHBSP suppressed adipogenesis, adipokine expression and peroxisome proliferator-activated receptor γ (PPARγ) levels during 3T3-L1 preadipocyte maturation through the EPO receptor (EPOR). In addition, also through EPOR, pHBSP attenuated macrophage inflammatory activation and promoted PPARγ expression. Furthermore, PPARγ deficiency partly ablated the anti-inflammatory activity of pHBSP in macrophages. Correspondingly, pHBSP administration to high-fat diet (HFD)-fed mice significantly improved obesity, insulin resistance (IR) and adipose tissue inflammation without stimulating hematopoiesis. Therefore, pHBSP can significantly protect against obesity and IR partly by inhibiting adipogenesis and inflammation. These findings have therapeutic implications for metabolic disorders, such as obesity and diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.